In one paragraphArticle in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Tatjana SelaRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.ORCID 0009-0000-5704-263X Tamara WirthRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.ORCID 0009-0003-2005-4882 Annika SommerRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Vincent LarrailletRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Joachim ButzerRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.ORCID 0009-0004-8109-9643 Sabine LohmannRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Pia WittmannRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Christian KleinRoche Pharma Research and Early Development, pRED, Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland.ORCID 0000-0001-7594-7280 Hendrik KnoetgenRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Roberto VillasenorRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0000-0002-0244-1091 Annette IndlekoferRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Kerstin HoferRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Felix SchumacherRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.ORCID 0009-0006-1546-1557 Jens NiewöhnerRoche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Antisense oligonucleotides (ASOs) represent a promising therapeutic modality for central nervous system (CNS) disorders, offering highly specific modulation of gene expression. However, their clinical utility is severely limited by their inability to cross the blood-brain barrier (BBB), necessitating effective shuttling strategies. While transferrin receptor (TfR1)-mediated shuttling has shown therapeutic promise, the fundamental mechanisms governing the delivery of antibody-ASO conjugates across the BBB remain poorly understood. This study directly addresses this critical knowledge gap by establishing a mechanistic understanding of how the ASO cargo impacts major cellular interactions during the Brainshuttle
Indexed as
Antibodies, BispecificBlood-Brain BarrierFusion Regulatory Protein-1Oligonucleotides, AntisenseReceptors, TransferrinAnimalsEndothelial CellsHumansTranscytosisAntibodies, BispecificFusion Regulatory Protein-1Oligonucleotides, AntisenseReceptors, TransferrinAffinityantibody engineeringantibody-oligonucleotide conjugatesASObispecific antibodiesBrainshuttleCD98hcCNSdeliveryTfRtranscytosis
Identifiers
PMID42332368
PMCPMC13290098
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390